JP2020537659A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537659A5 JP2020537659A5 JP2020521541A JP2020521541A JP2020537659A5 JP 2020537659 A5 JP2020537659 A5 JP 2020537659A5 JP 2020521541 A JP2020521541 A JP 2020521541A JP 2020521541 A JP2020521541 A JP 2020521541A JP 2020537659 A5 JP2020537659 A5 JP 2020537659A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- virus
- mycoplasmataceae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 241000204034 Mycoplasmataceae Species 0.000 claims description 14
- 208000035143 Bacterial infection Diseases 0.000 claims description 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 239000002911 sialidase inhibitor Substances 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 241001112741 Bacillaceae Species 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 4
- 241000588921 Enterobacteriaceae Species 0.000 claims description 4
- 241001248479 Pseudomonadales Species 0.000 claims description 4
- 206010042566 Superinfection Diseases 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical group CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 4
- 241000712431 Influenza A virus Species 0.000 claims description 3
- 241000713196 Influenza B virus Species 0.000 claims description 3
- 241000947836 Pseudomonadaceae Species 0.000 claims description 3
- 241001493065 dsRNA viruses Species 0.000 claims description 3
- 241000606069 Chlamydiaceae Species 0.000 claims description 2
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 claims description 2
- 241000589246 Legionellaceae Species 0.000 claims description 2
- 241000606752 Pasteurellaceae Species 0.000 claims description 2
- 241000295644 Staphylococcaceae Species 0.000 claims description 2
- 241000194018 Streptococcaceae Species 0.000 claims description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 2
- 229950004244 laninamivir Drugs 0.000 claims description 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 2
- 229960003752 oseltamivir Drugs 0.000 claims description 2
- 229960002194 oseltamivir phosphate Drugs 0.000 claims description 2
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 2
- 229960001084 peramivir Drugs 0.000 claims description 2
- 229960001028 zanamivir Drugs 0.000 claims description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940124647 MEK inhibitor Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 241000606161 Chlamydia Species 0.000 description 2
- 241000589248 Legionella Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023018912A JP7618276B2 (ja) | 2017-10-17 | 2023-02-10 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
| JP2024228526A JP2025031917A (ja) | 2017-10-17 | 2024-12-25 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LULU100487 | 2017-10-17 | ||
| LU100487 | 2017-10-17 | ||
| PCT/EP2018/078335 WO2019076947A1 (en) | 2017-10-17 | 2018-10-17 | NEW MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023018912A Division JP7618276B2 (ja) | 2017-10-17 | 2023-02-10 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537659A JP2020537659A (ja) | 2020-12-24 |
| JP2020537659A5 true JP2020537659A5 (OSRAM) | 2021-09-16 |
| JP7227967B2 JP7227967B2 (ja) | 2023-02-22 |
Family
ID=60484427
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521541A Active JP7227967B2 (ja) | 2017-10-17 | 2018-10-17 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
| JP2023018912A Active JP7618276B2 (ja) | 2017-10-17 | 2023-02-10 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
| JP2024228526A Pending JP2025031917A (ja) | 2017-10-17 | 2024-12-25 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023018912A Active JP7618276B2 (ja) | 2017-10-17 | 2023-02-10 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
| JP2024228526A Pending JP2025031917A (ja) | 2017-10-17 | 2024-12-25 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11903917B2 (OSRAM) |
| EP (2) | EP3973960B1 (OSRAM) |
| JP (3) | JP7227967B2 (OSRAM) |
| KR (1) | KR102848960B1 (OSRAM) |
| CN (2) | CN111479566B (OSRAM) |
| AU (2) | AU2018351475A1 (OSRAM) |
| BR (1) | BR112020007442A2 (OSRAM) |
| CA (1) | CA3078424A1 (OSRAM) |
| CY (1) | CY1124507T1 (OSRAM) |
| DK (1) | DK3697405T3 (OSRAM) |
| EA (1) | EA202090693A1 (OSRAM) |
| ES (2) | ES3041322T3 (OSRAM) |
| HR (1) | HRP20211252T1 (OSRAM) |
| HU (1) | HUE055738T2 (OSRAM) |
| LT (1) | LT3697405T (OSRAM) |
| MX (2) | MX2020003473A (OSRAM) |
| PL (1) | PL3697405T3 (OSRAM) |
| PT (1) | PT3697405T (OSRAM) |
| SI (1) | SI3697405T1 (OSRAM) |
| WO (1) | WO2019076947A1 (OSRAM) |
| ZA (1) | ZA202002069B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11903917B2 (en) * | 2017-10-17 | 2024-02-20 | Atriva Therapeutics Gmbh | MEK-inhibitor for the treatment of viral and bacterial infections |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| CA3149588A1 (en) | 2019-08-27 | 2021-03-04 | Oliver Planz | Combinations of mek inhibitors with cap-dependent endonuclease inhibitors |
| BR112022005896A2 (pt) * | 2019-10-08 | 2022-06-28 | Atriva Therapeutics Gmbh | Inibidores da mek para o tratamento de infecções causadas por hantavírus |
| ES2995196T3 (en) * | 2020-05-20 | 2025-02-07 | Atriva Therapeutics Gmbh | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
| CN112957361B (zh) * | 2021-03-24 | 2022-07-29 | 中国科学院武汉病毒研究所 | 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| EP1140067A1 (en) * | 1999-01-07 | 2001-10-10 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| TR200200082T2 (tr) * | 1999-07-16 | 2002-04-22 | Warner-Lambert Company | MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi. |
| DE10017480A1 (de) | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
| CA2473545A1 (en) | 2002-01-23 | 2003-07-31 | Warner-Lambert Company Llc | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| DE10300222A1 (de) * | 2003-01-03 | 2004-07-15 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen |
| JP2007055983A (ja) * | 2005-08-26 | 2007-03-08 | Tokyo Univ Of Science | 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤 |
| ES2575995T3 (es) | 2010-08-05 | 2016-07-04 | Case Western Reserve University | Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal |
| US9566281B2 (en) | 2012-10-08 | 2017-02-14 | Atriva Therapeutics Gmbh | MEK inhibitors in the treatment of virus diseases |
| CN116942832A (zh) * | 2014-05-16 | 2023-10-27 | 归属疗法有限公司 | 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略 |
| US11903917B2 (en) * | 2017-10-17 | 2024-02-20 | Atriva Therapeutics Gmbh | MEK-inhibitor for the treatment of viral and bacterial infections |
| BR112022005896A2 (pt) | 2019-10-08 | 2022-06-28 | Atriva Therapeutics Gmbh | Inibidores da mek para o tratamento de infecções causadas por hantavírus |
| ES2995196T3 (en) | 2020-05-20 | 2025-02-07 | Atriva Therapeutics Gmbh | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
-
2018
- 2018-10-17 US US16/756,720 patent/US11903917B2/en active Active
- 2018-10-17 EP EP21185183.7A patent/EP3973960B1/en active Active
- 2018-10-17 BR BR112020007442-0A patent/BR112020007442A2/pt active Search and Examination
- 2018-10-17 KR KR1020207013451A patent/KR102848960B1/ko active Active
- 2018-10-17 CA CA3078424A patent/CA3078424A1/en active Pending
- 2018-10-17 ES ES21185183T patent/ES3041322T3/es active Active
- 2018-10-17 SI SI201830351T patent/SI3697405T1/sl unknown
- 2018-10-17 MX MX2020003473A patent/MX2020003473A/es unknown
- 2018-10-17 EP EP18800045.9A patent/EP3697405B1/en active Active
- 2018-10-17 PT PT188000459T patent/PT3697405T/pt unknown
- 2018-10-17 HR HRP20211252TT patent/HRP20211252T1/hr unknown
- 2018-10-17 PL PL18800045T patent/PL3697405T3/pl unknown
- 2018-10-17 CN CN201880081184.5A patent/CN111479566B/zh active Active
- 2018-10-17 JP JP2020521541A patent/JP7227967B2/ja active Active
- 2018-10-17 LT LTEPPCT/EP2018/078335T patent/LT3697405T/lt unknown
- 2018-10-17 WO PCT/EP2018/078335 patent/WO2019076947A1/en not_active Ceased
- 2018-10-17 ES ES18800045T patent/ES2883639T3/es active Active
- 2018-10-17 DK DK18800045.9T patent/DK3697405T3/da active
- 2018-10-17 CN CN202410133936.5A patent/CN118141795A/zh active Pending
- 2018-10-17 HU HUE18800045A patent/HUE055738T2/hu unknown
- 2018-10-17 EA EA202090693A patent/EA202090693A1/ru unknown
- 2018-10-17 AU AU2018351475A patent/AU2018351475A1/en not_active Abandoned
-
2020
- 2020-05-04 ZA ZA2020/02069A patent/ZA202002069B/en unknown
- 2020-07-13 MX MX2022016066A patent/MX2022016066A/es unknown
-
2021
- 2021-08-24 CY CY20211100757T patent/CY1124507T1/el unknown
-
2023
- 2023-02-10 JP JP2023018912A patent/JP7618276B2/ja active Active
-
2024
- 2024-02-16 US US18/443,904 patent/US20240245637A1/en active Pending
- 2024-08-16 AU AU2024205853A patent/AU2024205853A1/en active Pending
- 2024-12-25 JP JP2024228526A patent/JP2025031917A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537659A5 (OSRAM) | ||
| HRP20211252T1 (hr) | Novi mek-inhibitor za liječenje virusnih i bakterijskih infekcija | |
| CN102325532B (zh) | 用于减轻肺部炎症的左氧氟沙星吸入剂 | |
| JP2015534562A5 (OSRAM) | ||
| JP2018021046A5 (OSRAM) | ||
| JP2015517489A5 (OSRAM) | ||
| JP2011173928A5 (OSRAM) | ||
| JP2015083580A5 (OSRAM) | ||
| JP2015529225A5 (OSRAM) | ||
| JP2015523407A5 (OSRAM) | ||
| JP2018513188A5 (OSRAM) | ||
| JP2021152008A5 (OSRAM) | ||
| BR112015010396A2 (pt) | terapia de combinação | |
| IL307992A (en) | Parasitic formulations containing isoxazoline and methods for treating blepharitis | |
| CN110769824B (zh) | 用于治疗和/或预防细菌继发性感染的il-8抑制剂 | |
| KR20190073365A (ko) | 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제 | |
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| JP2017526714A5 (OSRAM) | ||
| HRP20211749T1 (hr) | Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom | |
| JP2020524689A5 (OSRAM) | ||
| JP2020529995A5 (OSRAM) | ||
| JP2015531384A (ja) | インバリアントｎｋｔ細胞アゴニストを用いたインフルエンザ後の細菌重複感染の予防的処置のための方法及び薬学的組成物 | |
| JP2018526345A5 (OSRAM) | ||
| JP2020510045A5 (OSRAM) | ||
| WO2020128816A3 (en) | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent |